Sulforaphane prenatal supplement for preventing fetal brain injury and cerebral palsy

Overview

This research program investigates sulforaphane (SFA), a natural compound derived from broccoli sprouts, as a prenatal dietary supplement to protect the developing fetal brain from injury. The work addresses cerebral palsy and childhood developmental disabilities linked to placental insufficiency. Prior rodent studies demonstrated that broccoli sprout supplementation during pregnancy prevents white matter injury and improves developmental milestones in offspring, with benefits persisting into adulthood. The current focus is establishing a precise dose-response and safety curve to support translation to human Phase 1 clinical trials.

Technical specifications

Mechanism of action:

• SFA is a phase II enzyme inducer with antioxidant and anti-inflammatory properties
• Activates the Nrf2 pathway, enhancing the endogenous glutathione reducing system for free-radical neutralization
• Most effective at very low doses; high doses have been shown to increase apoptosis and cell death, underscoring the need for precise dosing

Validated outcomes in rodent models:

• Reduced white matter injury, a hallmark pathological feature of cerebral palsy
• Improved developmental milestone acquisition in offspring
• Enhanced brain connectivity through increased dendritic arborization and synaptogenesis
• Benefits sustained through adulthood with no abnormalities in control offspring receiving supplementation

Current and planned validation:

• Testing low, medium, and high SFA concentrations in normal pregnant rodents across three timing groups: beginning of pregnancy, second trimester, and third trimester
• SFA delivered via 'jello-cubes' for controlled daily dosing throughout gestation
• Blood SFA levels measured at the end of each trimester
• Offspring evaluated for developmental reflexes, memory, anxiety, and motor coordination through 60 days postnatal age
• Necropsy and histological pathology of brain, kidney, liver, and lung for safety assessment

Technology readiness level

The technology is at an early-to-mid preclinical stage. Proof-of-concept efficacy has been established in a validated rodent model of placental insufficiency (bilateral uterine artery ligation), with demonstrated histopathological and behavioral benefits persisting long-term. Current efforts are focused on generating the dose-response and safety data required to advance toward human Phase 1 clinical trials. Funding is sought for technical assistance, animal maintenance, and pathology services to complete these validation studies.